Asset Details
Do you wish to reserve the book?
EBM BLS: Adding tirzepatide to long-acting insulin is superior to adding mealtime insulin for type 2 diabetes mellitus
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
EBM BLS: Adding tirzepatide to long-acting insulin is superior to adding mealtime insulin for type 2 diabetes mellitus
Do you wish to request the book?
EBM BLS: Adding tirzepatide to long-acting insulin is superior to adding mealtime insulin for type 2 diabetes mellitus
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
EBM BLS: Adding tirzepatide to long-acting insulin is superior to adding mealtime insulin for type 2 diabetes mellitus
2024
Overview
[...]adherence to these regimens is difficult and hypoglycemia and weight gain are common side effects.1 A previous study demonstrated that tirzepatide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and gastric inhibitory polypeptide (GIP) receptor agonist, was superior to long-acting insulin for Hgb A1c reduction.2 This randomized controlled trial evaluated the effectiveness of tirzepatide to reduce hemoglobin A1c compared with mealtime insulin (insulin lispro) for people with type 2 DM taking basal insulin.3 Results 1,428 patients were randomized in the study. For patients randomized to tirzepatide, the pooled average Hgb A1c was reduced by 2.1% (to 6.69%) compared with a reduction of HbgA1c of 1.13% (to 7.67%) for patients randomized to insulin lispro, an absolute difference of -0.98% between groups (95% CI -1.17 to -0.79%, p < 0.001) (Fig. 1). The study assessed multiple outcomes important to patients included Hgb A1c, weight loss, and hypoglycemia events.
Publisher
Springer Nature B.V
